ACTR1A has pleiotropic effects on risk of leprosy, inflammatory

bowel disease and atopy

2

3

James J Gilchrist^{1,2,3}*, Kathryn Auckland³, Tom Parks^{3,4},

Alexander J Mentzer³, Lily Goldblatt⁵, Vivek Naranbhai³, Gavin Band³,

Kirk A Rockett³, Ousmane B Toure⁶, Salimata Konate⁶, Sibiri Sissoko⁶,

Abdoulaye A Djimdé⁶, Mahamadou A Thera⁶, Ogobara K Doumbo^{6†},

Samba Sow⁷, Sian Floyd⁸, Jörg M Pönnighaus⁹, David K Warndorff⁹,

Amelia C Crampin⁹, Paul EM Fine⁸, Benjamin P Fairfax², Adrian VS Hill^{3,10}*

4	¹ Department of Paediatrics, University of Oxford, Oxford, UK
5	2 MRC–Weather all Institute of Molecular Medicine, University of Oxford, Oxford, UK
6	$^{3}\mathrm{Wellcome}$ Centre for Human Genetics, University of Oxford, Oxford, UK
7	⁴ Department of Infectious Diseases, Imperial College London, London, UK.
8	⁵ Balliol College, Oxford, UK.
9	⁶ Malaria Research and Training Centre, University of Science, Techniques and Technologies of Bamako, Bamako, Mali.
10	⁷ Center for Vaccine Development, Bamako, Mali.
11	⁸ Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
12	⁹ Malawi Epidemiology and Intervention Research Unit (formerly Karonga Prevention Study), Chilumba, Malawi.
13	¹⁰ Jenner Institute, University of Oxford, Oxford, UK.
14	*Corresponding authors
15	Email: james.gilchrist@paediatrics.ox.ac.uk (JJG), adrian.hill@ndm.ox.ac.uk (AVSH)
16	† Deceased
17	January 27, 2022

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18 Abstract

Leprosy is a chronic infection of the skin and peripheral nerves caused by *Mycobacterium leprae*. De-19 spite recent improvements in disease control, leprosy remains an important cause of infectious disability 20 globally. Large-scale genetic association studies in Chinese, Vietnamese and Indian populations have 21 identified over 30 susceptibility loci for leprosy. There is a significant burden of leprosy in Africa, how-22 ever it is uncertain whether the findings of published genetic association studies are generalizable to 23 African populations. To address this, we conducted a genome-wide association study (GWAS) of leprosy 24 in Malawian (327 cases, 436 controls) and Malian (247 cases, 368 controls) individuals. In that analysis, 25 we replicated five risk loci previously reported in China, Vietnam and India; MHC Class I and II, LACC1 26 (2 independent loci) and SLC29A3. We further identified a novel leprosy susceptibility locus at 10q24 27 (rs2015583: combined $p = 8.81 \times 10^{-9}$; OR = 0.51 [95% CI 0.40 - 0.64]). The leprosy risk locus is 28 a determinant of ACTR1A RNA expression in CD4⁺ T cells (posterior probability of colocalization -29 PP = 0.96). Furthermore, it demonstrates pleiotropy with established risk loci for inflammatory bowel 30 disease and atopic disease. Reduced ACTR1A expression decreases susceptibility to leprosy and atopy 31 but increases risk of inflammatory bowel disease. A shared genetic architecture for leprosy and inflam-32 matory bowel disease has been previously described. We expand on this, strengthening the evidence that 33 selection pressure driven by leprosy has shaped the evolution of autoimmune and atopic disease in mod-34 ern populations. More broadly, our data highlights the importance of defining the genetic architecture 35 of disease across genetically diverse populations, and that disease insights derived from GWAS in one population may not translate to all affected populations. 37

³⁸ Author Summary

Leprosy remains a leading cause of infectious disability globally. Human genetic variation is a major 39 determinant of susceptibility to infection, including leprosy. Large-scale genetic association studies have 40 been pivotal in advancing our understanding of leprosy biology. These studies have been performed in 41 Chinese, Vietnamese and Indian populations, and it remains unclear whether these insights are infor-42 mative of leprosy susceptibility in African populations. To address this, we performed a genome-wide 43 association study of leprosy susceptibility in Malawi and Mali. In doing so we replicate known leprosy susceptibility loci at MHC class I and II, LACC1 and SLC29A3. Furthermore, we identify a novel leprosy 45 susceptibility locus, which modifies expression of ACTR1A in CD4⁺ T cells and demonstrates pleiotropy 46 with inflammatory bowel disease (IBD) and atopic disease. These data deepen our understanding of 47 leprosy biology, identifying ACTR1A expression in CD4⁺ T cells as a determinant of leprosy disease 48 risk, and further define the role of this ancient pathogen in the evolution of immune-mediated diseases 49 in modern populations. 50

51 Introduction

Leprosy is a chronic infectious disease affecting the skin and peripheral nerves caused by Mycobacterium 52 leprae. It is a leading infectious cause of disability (Britton & Lockwood, 2004). The introduction of 53 multidrug therapy ("Chemotherapy of leprosy. Report of a WHO Study Group.", 1994), widespread 54 use of BCG vaccination (Pönnighaus et al., 1992), and the 1991 World Health Assembly resolution to 55 eliminate leprosy by the year 2000 have all contributed to a decline in disease burden; nevertheless, 56 over 200,000 new cases continue to be reported annually (https://www.who.int/gho/neglected_diseases/ 57 leprosy/en/), numbers which are likely to represent a considerable underestimate of the true disease 58 burden (Smith et al., 2015). 59

Large-scale, unbiased genetic association studies in Chinese (Liu et al., 2015; Liu et al., 2017; Wang 60 et al., 2018; Wang et al., 2016; F.-R. Zhang et al., 2009; F. Zhang et al., 2011), Indian (Wong et al., 61 2010) and Vietnamese (Gzara et al., 2020) populations have identified and validated 34 genetic loci 62 independently associated with leprosy outside the HLA region, as well as independent HLA class I and 63 class II associations. A key feature of these studies has been the demonstration of considerable genetic 64 heterogeneity in leprosy susceptibility between populations. For instance, while genetic variation at TLR1 65 associates with leprosy risk in Indian and Turkish populations, this finding has not been replicated in 66 Chinese and Vietnamese populations. To date, there are no published genome-wide association studies 67 (GWAS) of leprosy in African populations. This is important as there remains a significant burden of 68 leprosy in Africa and the observed inter-population heterogeneity reported in the Chinese, Vietnamese 69 and Indian studies suggest that the published GWAS findings may not be generalizable to African 70 populations. To address this, we have performed a GWAS of leprosy susceptibility in Malawian and 71 Malian individuals. 72

$_{73}$ Results

⁷⁴ Leprosy genome-wide association study

Individuals with leprosy were recruited to the study following clinical and microbiological evaluation 75 within the Karonga Prevention Study (KPS), Karonga, Malawi. Healthy controls were recruited from 76 the same population. Following quality control and genome-wide imputation, genotypes at 10,511,695 77 loci from 612 samples (284 cases, 328 controls) were included in the association analysis. Inspection of 78 the QQ plot (Supplementary Fig. 1) and the genomic inflation parameter ($\lambda = 1.0333$) demonstrates 79 that inclusion of the six major principal components as covariates in the model adequately controls for 80 confounding variation. In that analysis, we identified 142 loci, representing 38 independent genomic 81 loci, with suggestive evidence of association $(p < 1 \times 10^{-5})$ with leprosy in Malawian populations 82






Figure 1: Manhattan plot of leprosy in Malawi and Mali. Evidence for association with leprosy at genotyped and imputed autosomal SNPs and indels (n = 9, 616, 523) in Malawi and Mali (492 cases, 639 controls). Association statistics represent a fixed-effects meta-analysis of additive association with disease in Malawi and Mali. The red, dashed line denotes genome-wide significance $(p = 5 \times 10^{-8})$.

(Supplementary Fig. 2, Supplementary Table 1). 83

GWAS replication and meta-analysis 84

We sought to replicate evidence for leprosy association observed in Malawi among leprosy cases and 85 healthy controls in Mali. Individuals with leprosy were recruited to the study at Mali's former national 86 leprology centre, Institut Marchoux, (now Hôpital Dermatologique de Bamako), Bamako. Healthy con-87 trols were recruited from the same population. Among the Malian samples, 10,514,676 loci and 519 88 individuals (208 cases, 311 controls) passed QC filters. The QQ plot (Supplementary Fig. 1) and 89 genomic inflation parameter ($\lambda = 1.0498$) of genome-wide association analysis in the Malian samples 90 demonstrates control of confounding variation with inclusion of the major six major principal compo-91 nents and genotyping platform as covariates in the model. We combined evidence for leprosy association 92 in Malawi and Mali using a fixed-effects meta-analysis (Fig. 1). Of the 142 leprosy-associated loci identi-93 fied in the discovery analysis, 18 SNPs, at a single genomic locus at 10q24.32 (Fig. 2A), showed evidence 94 of replication in Mali (p < 0.05) and overall evidence of association with leprosy exceeding genome-wide 95 significance $(p < 5 \times 10^{-8})$. The variant with the strongest evidence for leprosy association at that locus 96 is rs2015583: $p = 8.81 \times 10^{-9}$, OR = 0.51 (95% CI 0.40 - 0.64). There is no evidence for heterogeneity of 97 effect between populations at rs2015583 (heterogeneity p = 0.871, Fig. 2B), and the data best supports 98 a model in which rs2015583 modifies risk of both paucibacillary and multibacillary leprosy (log10 Bayes 99 factor = 6.01, Fig. 2B). 100

Fine-mapping of the leprosy association at chr10q24.32 identifies a credible set of 19 SNPs with a 101 95% probability of containing the causal variant, spanning a 6kb region: chr10:104,226,830-104,232,809 102 (Supplementary Table 2). Genetic variation at this locus has not been previously described as a de-103 terminant of leprosy risk. In keeping with the observation that the human genetics of leprosy risk is 104 characterized by considerable heterogeneity of effect between populations, there is no evidence for leprosy 105 106

OR = 0.98) or at any of the 19 variants in the credible SNP set (Dr Z Wang and Prof. F Zhang, personal communication, November 2019).

¹⁰⁹ A leprosy risk locus modifies ACTR1A expression in CD4⁺ T cells

Trait-associated genetic variation identified by GWAS are highly enriched for regulatory variation. To 110 explore whether leprosy-associated genetic variation at chr10q24.32 modifies leprosy risk through its 111 effect on gene expression, we investigated whether the leprosy risk locus colocalizes with expression 112 quantitative trait loci (eQTL) in a range of primary immune cells; monocytes (Fairfax et al., 2014), B 113 cells (Fairfax et al., 2012), NK cells (Gilchrist et al., 2021), neutrophils (Naranbhai et al., 2015), CD4⁺ 114 T cells and CD8+ T cells (Kasela et al., 2017). These data demonstrate colocalization of the leprosy risk 115 locus at chr10q24.32 with an eQTL for ACTR1A expression in CD4⁺ T cells (posterior probability of 116 colocalization, PP4 = 0.94), but not gene expression in other cell types (Fig. 2C, Supplementary Table 117 3). The leprosy protective allele, rs2015583:G, is associated with reduced ACTR1A expression in CD4+ 118 T cells $(p = 4.69 \times 10^{-9}, \beta = -0.085).$ 119

ACTR1A expression has pleiotropic effects on risk of immune-mediated disease

A key of feature of genetic determinants of leprosy described to date has been the identification of 122 pleiotropy at leprosy risk loci with other immune-mediated diseases, in particular inflammatory bowel 123 disease (Jostins et al., 2012; Sun et al., 2016). To explore whether leprosy-associated genetic variation 124 modifying ACTR1A expression is a determinant of other immune-mediated diseases in human popula-125 tions, we assessed evidence of colocalization at the $CD4^+$ T cell ACTR1A eQTL with immune-mediated 126 diseases (n=29) and haematological traits (n=26). In that analysis (Fig. 2D, Supplementary Table 4), 127 in addition to leprosy, the ACTR1A eQTL in CD4⁺ T cells colocalizes with four immune-mediated dis-128 eases (inflammatory bowel disease, atopy, childhood-onset asthma and hayfever), and four haematological 129 traits (white cell count, neutrophil count, mean corpuscular volume and mean corpuscular haemoglobin). 130 Decreased ACTR1A expression in CD4⁺ T cells is associated with perturbations of haematological in-131 dices (increased neutrophil and white cell counts, decreased mean corpuscular haemoglobin and volume), 132 increased risk of inflammatory bowel disease and decreased risk of atopy (atopy as a composite trait, 133 childhood-onset asthma and hayfever). 134

¹³⁵ Replication of leprosy HLA associations

The observation that class I and II HLA alleles are key determinants of leprosy risk has been highly reproducible across diverse populations (Gzara et al., 2020; Wang et al., 2016; Wong et al., 2010).







Figure 2: Leprosy association, regulatory function and pleiotropy at chromosome 10q24.32. (A) Regional association plot of leprosy association at chr10q24.32. Association statistics represent a fixed-effects meta-analysis of additive association with disease in Malawi and Mali. SNPs are coloured according to linkage disequilibrium to rs2015583, and genotyped SNPs marked with black plusses. (B) Log-transformed odds ratios and 95% confidence intervals of rs2015583 association with leprosy in Malawi and Mali (top) and stratified by multibacillary and paucibacillary disease (middle). Posterior probabilities of models of rs2015583 association with leprosy: "Null", no association with leprosy; "MB", non-zero effect in multibacillary leprosy alone; "PB", non-zero effect in paucibacillary leprosy alone: "Both", the same non-zero effect is shared by individuals with multibacillary and paucibacillary leprosy. (C) Log-transformed odds ratios and 95% confidence intervals of rs2015583 association with gene expression in primary immune cells (top). Associations which colocalize with the leprosy association signal (ACTR1A expression in CD4⁺ T cells) are highlighted in pink. The ACTR1A eQTL in CD4+ T cells colocalizes with the risk locus for leprosy at chr10q24.32 (bottom). SNPs are coloured according to linkage disequilibrium to rs2015583 as above. (D) Log-transformed odds ratios and 95%confidence intervals of rs2015583 association (top) with immune-mediated diseases (IBD, inflammatory bowel disease; atopy; hayfever; childhood-onset asthma) and hematological indices (WCC, white cell count; Neut, neutrophil count; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin). The ACTR1A eQTL in CD4⁺ T cells colocalizes with the GWAS locus for each trait at chr10q24.32 (bottom). SNPs are coloured according to linkage disequilibrium to rs2015583 as above.

Motivated by this, and by evidence of association in the HLA observed in our data (Fig. 1), we explored 138 evidence for leprosy association in the HLA in Malawi and Mali at the level of SNPs and classical HLA 139 alleles. In a fixed-effects meta-analysis of leprosy association in Malawi and Mali (Fig. 3A, Supplementary 140 Table 5), the peak classical allele association is a class II allele: HLA-DQB1*04:02 ($p = 6.74 \times 10^{-5}$, 141 FDR = 0.0063, OR = 2.1.95% CI 1.75 - 2.51). We also observed a leprosy association in the class I 142 region, at HLA-B*49:01 ($p \times 6.02 \times 10^{-4}$, FDR = 0.0156), which is independent of HLA-DQB1*04:02 143 (Supplementary Fig. 3). No significant residual associations were observed after conditioning on both 144 DQB1*04:02 and HLA-B*49:01 (Supplementary Fig. 4). There is no evidence for heterogeneity of effect 145 between populations at HLA-DQB1*04:02 or HLA-B*49:01 (heterogeneity p = 0.8836 and p = 0.7049, 146 Fig. 3B), and the data best supports a model in which both HLA-DQB1*04:02 and HLA-B*49:01 modify 147 risk of both paucibacillary and multibacillary leprosy ($\log 10$ Bayes factors = 2.22 and 0.43 respectively, 148 Fig. 3C,D). 149

¹⁵⁰ Replication of known leprosy associations outside the HLA

Our identification of a genetic variant modifying leprosy risk in African populations, but not in Chinese 151 populations, highlights the inter-population heterogeneity that has been observed across large-scale ge-152 netic studies of leprosy susceptibility (Gzara et al., 2020; Wang et al., 2016; Wong et al., 2010). Our 153 study has adequate power (> 80%) to replicate (p < 0.05) findings at 7 of 34 previously-published leprosy 154 risk loci outside the HLA (Supplementary Table 6). We were able to replicate leprosy associations at 155 2 loci (Fig. 4A); a missense SNP in LACC1, rs3764147 (p = 0.004, OR = 1.36 95% CI 1.10 - 1.67), 156 and a missense SNP in *SLC29A3*, rs780668 (p = 0.034, OR = 1.28 95% CI 1.02 - 1.60). There is 157 no evidence for heterogeneity of effect between populations at rs3764147 or rs780668 (heterogeneity 158 p = 0.444 and p = 0.159, Fig. 4A), and the data best supports a model in which both rs3764147 and 159 rs780668 modify risk of both paucibacillary and multibacillary leprosy (log10 Bayes factors = 1.64 and 160 0.68 respectively, Fig. 4B,C). Among the 6 loci at which we were not able to demonstrate replication of 161 previously-published leprosy association despite adequate study power, there is no evidence that our lack 162 of replication reflects effects restricted to multibacillary or paucibacillary disease (Supplementary Table 163 7). We further considered whether our failure to replicate previously-reported leprosy associations could 164 represent differential linkage disequilibrium to an undefined causal locus between study populations. To 165 test this, we examined evidence for leprosy association within 250kb of each previously-reported leprosy 166 risk locus outside the HLA. In that analysis we identified a promoter variant in RAB32, rs34271799, 167 with suggestive evidence of association with leprosy risk in Malawi and Mali ($p_{MALAWI} = 0.0023$, 168 $p_{MALI} = 0.0034, p_{COMBINED} = 6.00 \times 10^{-5}; OR = 0.42, 95\% CI = 0.28 - 0.64,$ Supplementary Fig. 169 5). There was no evidence suggestive of leprosy association $(p < 1 \times 10^{-4})$ within 250kb of any other 170 previously identified leprosy risk locus. 171





(A) Regional association plot of leprosy association across the HLA region. Association statistics represent a fixed-effects meta-analysis of additive association with disease in Malawi and Mali. SNPs are coloured according to linkage disequilibrium to rs9270926, and genotyped SNPs marked with black plusses. Imputed classical HLA alleles are plotted as diamonds, with significantly associated (FDR < 0.05) alleles highlighted in blue. (B) Log-transformed odds ratios and 95% confidence intervals of HLA-DBQ1*04:02 and HLA-B*49:01 associations with leprosy in Malawi and Mali. (C) Log-transformed odds ratios and 95% confidence intervals of HLA-DBQ1*04:02 and HLA-B*49:01 associations with leprosy stratified by multibacillary and paucibacillary disease. (D) Posterior probabilities of models of HLA-DBQ1*04:02 and HLA-B*49:01 associations with leprosy: "Null", no association with leprosy; "MB", non-zero effect in multibacillary leprosy alone; "PB", non-zero effect in paucibacillary leprosy alone; "Both", the same non-zero effect is shared by individuals with multibacillary and paucibacillary leprosy.




Figure 4: Replication of leprosy associations at LACC1 and SLC29A3 in Malawi and Mali. (A) Log-transformed odds ratios and 95% confidence intervals of rs3764147 and rs780668 associations with leprosy in Malawi and Mali. (B) Log-transformed odds ratios and 95% confidence intervals of rs3764147 and rs780668 associations with leprosy stratified by multibacillary and paucibacillary disease. (C) Posterior probabilities of models of rs3764147 and rs780668 associations with leprosy: "Null", no association with leprosy; "MB", non-zero effect in multibacillary leprosy alone; "PB", non-zero effect in paucibacillary leprosy alone; "Both", the same non-zero effect is shared by individuals with multibacillary and paucibacillary leprosy.

172 Discussion

In this study, we demonstrate that genetic variation at chromosome 10q24.32 is a determinant of leprosy risk in African populations. In common with many examples of trait-associated genetic variation identified by GWAS (Maurano et al., 2012), variation at 10q24.32 modifies risk of leprosy through regulatory effects on gene expression, specifically *ACTR1A* expression in CD4⁺ T cells. We expand upon this, identifying evidence of pleiotropy at 10q24.32, demonstrating a shared genetic architecture of leprosy, inflammatory bowel disease and atopy at this locus. Furthermore, we replicate previously identified leprosy susceptibility loci at *LACC1*, *SLC29A3*, and with HLA Class I and II alleles.

ACTR1A encodes actin-related protein-1 (ARP1), a component of the dynactin complex. Dynactin 180 interacts with the cytoplasmic motor, dynein, facilitating intracellular trafficking of a wide range of intra-181 cellular cargos (Roberts et al., 2013; Urnavicius et al., 2015). In T cells specifically, dynactin/dynein com-182 plexes direct the accumulation of TCRs and secretory vesicles at the immunological synapse (Hashimoto-183 Tane et al., 2011; Nath et al., 2016), and are required for nuclear translocation of NF κ B in response to T 184 cell stimulation (Shrum et al., 2009). The identification of a CD4⁺ T cell-specific eQTL as a determinant 185 of leprosy reflects the established role of T cell-mediated immunity in leprosy biology. The spectrum of 186 leprosy disease is defined by host T cell responses, with tuberculoid disease being characterised by ro-187 bust $CD4^+$ T cell IFN γ responses and patients with lepromatous disease failing to mount anti-M. leprae 188 cell-mediated responses (Yamamura et al., 1992). Similarly, leprosy reversal reactions, characterised by 189 painful inflammation of leprosy lesions, are association with infiltration of IFN γ producing CD4⁺ T cells 190 (Britton, 1998). In addition, the highly reproducible association between MHC class II alleles and lep-191 rosy strongly suggests a role for *M. leprae* antigen presentation as a determinant of leprosy susceptibility 192 per se. Our data are complementary to these observations, suggesting a model in which $CD4^+$ T cell 193 activation, determined at the level of the T cell as well as that of the antigen presenting cell, modifies 194 susceptibility to leprosy. 195

The identification of a CD4⁺ T cell-specific eQTL as a risk locus for inflammatory bowel disease 196 and atopy is consistent with the known biology of autoimmune and atopic disease. GWAS-identified 197 risk loci for both autoimmune and atopic disease are highly enriched for regulatory variation active in 198 CD4⁺ T cells, in particular regulatory CD4⁺ T cells (Bossini-Castillo et al., 2019). Our data provide 199 further support for the observation that leprosy and inflammatory bowel disease have a shared genetic 200 architecture (Jostins et al., 2012). We expand on this observation, suggesting a model in which selection 201 pressure imposed by *M. leprae* has shaped the evolution of atopic disease and autoimmune disease in 202 modern populations. 203

Our identification of a genetic locus modifying leprosy susceptibility in African populations, but with no effect on leprosy risk in well-powered GWAS in Chinese populations, is consistent with the existence of heterogeneity of genetic architecture of leprosy risk between populations. In keeping with this, we

observe no evidence of leprosy association in Malawi or Mali at 6 of the 7 non-HLA loci at which we have 207 adequate study power to assess this. We hypothesized that some of these inter-population differences 208 may reflect differential effects of genetic risk loci on multibacillary and paucibacillary disease, however we 209 find no evidence to support this in our data. Differential linkage disequilibrium between assayed variation 210 and a shared causal locus may explain some of the observed inter-population genetic heterogeneity of 211 leprosy risk. In keeping with this we observe modest evidence of leprosy association at RAB32, which is 212 distinct from that reported in Chinese populations. Understanding whether genetic variation at RAB32 213 is associated with leprosy risk in African populations, and whether this is distinct from that observed in 214 Chinese populations, will require replication in additional study populations. 215

Here we define regulatory variation at ACTR1A as a novel determinant of leprosy susceptibility in 216 African populations. Moreover, regulatory variation at ACTR1A has pleiotropic effects on hematological 217 indices in European populations and risk of IBD and atopy. A shared genetic architecture for leprosy 218 and IBD has been previously described. We expand on this, strengthening the evidence that selection 219 pressure driven by leprosy has shaped the evolution of immune-mediated disease in modern populations. 220 Our colocalization analyses identify ACTR1A as a potential therapeutic target for autoimmune and 221 atopic disease, and deepens our understanding of leprosy biology, which will be key in informing the 222 development of novel control strategies. More broadly, our data highlights the importance of defining 223 the genetic architecture of disease across genetically diverse populations, and that disease insights derived 224 from GWAS in one population may not readily translate to all affected populations. 225

²²⁶ Materials and methods

227 Ethics and consent

All cases and controls were recruited following informed consent of the participant or their parent/guardian. 228 The study protocol detailing recruitment and sample collection within KPS, Malawi was approved by the 229 National Health Sciences Research Committee of Malawi and by the Ethics Committee of the London 230 School of Hygiene and Tropical Medicine. The study protocols detailing recruitment and sample collec-231 tion at the Institut Marchoux, Mali and at the Centre Hospitalier Universitaire Gabriel Toure, Bamako, 232 Mali were approved by the University of Bamako Ethics Review Board. Genotyping and imputation for 233 additional Malian controls were collected as part of the MalariaGEN project, for which the study pro-234 tocol was reviewed by Oxford University Tropical Research Ethics committee (OXTREC), Oxford, UK 235 (OXTREC 020–006). The overall study design, including re-appraisal of study samples using genome-236 wide genotyping, was reviewed and approved by Oxford University Tropical Research Ethics committee 237 (OXTREC), Oxford, UK (OXTREC 560-15). 238

239 Study Participants

Leprosy case and control samples were recruited to the study in Karonga, Malawi and Bamako, Mali. Participant recruitment in Malawi (Fitness et al., 2004; Wallace et al., 2004) and Mali (Meisner et al., 2001) have been described previously. In brief, cases of leprosy were diagnosed in both settings on the basis of clinical examination, split skin smear and histopathologic examination of biopsy material. Adults or children with "certain" or "probable" cases were considered eligible for recruitment (Ponnighaus et al., 1987). Cases were further defined as having paucibacillary (PB) or multibacillary (MB) disease on the basis of clinical examination and bacteriological index > 1 on slit-skin smear or biopsy.

In Malawi, cases (n=327) and controls (n=436) were recruited to the study within the KPS, a longterm community-based, epidemiological study in Northern Malawi (Ponninghaus et al., 1987). Leprosy cases were identified through active population surveys in the 1980s, followed by enhanced passive case detection in the 1990s. Control samples were individuals within the KPS with no history or clinical features of leprosy, matched to case samples with respect to age, sex and geographic area of residence.

In Mali, between April and June 1997, patients with leprosy (n=247) presenting to Institut Marchoux, 252 Bamako, Mali (formerly Mali's national leprology center now Hôpital Dermatologique de Bamako) were 253 recruited to the study as described previously (Meisner et al., 2001). Control participants (n=185), 254 following exclusion of leprosy by clinical examination and history, were recruited in the same study 255 setting among hospital staff and patients with diagnoses other than leprosy. In addition, we supplemented 256 control numbers in the Malian replication study using healthy control samples (n=183), also recruited 257 in Bamako, collected as part of the MalariaGEN project (Malaria Genomic Epidemiology, 2019; Toure 258 et al., 2012). 259

Cases in Malawi were recruited at a median age of 47 years (range 15 to 83 years) and 187 were 260 female (57%). Among leprosy cases in Malawi, 47 had multibacillary disease and 275 paucibacillary 261 disease. Control samples in Malawi were recruited at a median age of 44 years (range 15 to 82 years) 262 and 273 were female (63%). Cases in Mali were recruited at a median age of 45 years (range 13 to 85 263 years) and 136 (55%) were female. Among leprosy cases in Mali, 165 had multibacillary disease and 82 264 paucibacillary disease. Control samples in Mali were recruited at a median age of 30 years (range 14 265 to 72 years) and 113 were female (62%). Additional MalariaGEN control samples were recruited at a 266 median age of 3 years (range 0 to 15 years) and 91 (50%) were female. 267

268 Genotyping

Genomic DNA was extracted from study samples as described previously (Fitness et al., 2004; Meisner et al., 2001). Following quantification (Ahn et al., 1996), samples were genotyped using the Illumina African Diaspora Power Chip platform (Johnston et al., 2017) and genotypes called using GenCall in GenomeStudio (Illumina). Using consensus strand information from the array manifest file and a

²⁷³ remapping pipeline (Dr William Rayner, Wellcome Centre for Human Genetics, Oxford) we aligned ²⁷⁴ genotypes such that all alleles are on the forward strand. Throughout genetic positions reflect GRCh37.

275 Sample quality control

We calculated per sample quality control (QC) metrics in PLINK (Purcell et al., 2007). For each sample 276 we calculated the proportion of missing genotype calls, heterozygosity and the mean X and Y channel 277 intensities. We plotted mean X and Y channel intensities (Supplementary Fig. 6) and missingness against 278 heterozygosity (Supplementary Fig. 7), defining outlier samples using ABERRANT (Bellenguez et al., 279 2012). We used PLINK to estimate sample sex from genotype data, excluding samples with discordant 280 genotype and metadata sex information. To identify duplicated and related samples, we calculated 281 pairwise relatedness between samples in PLINK. We considered samples with relatedness > 0.75 to 282 be duplicates, and additionally identified samples with relatedness > 0.2. In both cases we retained 283 the sample with the highest genotyping call rate of a duplicated/related sample pair. We calculated 284 principal components (PC) in EIGENSTRAT (Price et al., 2006). To identify population outliers, we 285 plotted study sample PCs against a background of African Genome Variation Project (Gurdasani et 286 al., 2015) samples, identifying outliers by visual inspection (Supplementary Fig. 8). For both PC and 287 relatedness computations we used an LD-pruned SNP set with regions of high linkage disequilibrium 288 (LD) excluded. The first two major principal components differentiate self-reported ethnicity in both 289 Malawi (Supplementary Fig. 9) and Mali (Supplementary Fig. 10). 290

²⁹¹ SNP quality control

Prior to genome-wide imputation, we extracted genotypes from non-duplicated, autosomal SNPs and applied the following SNP QC filters; SNP missingness > 10%, minor allele frequency (MAF) < 1%, Hardy-Weinberg equilibrium (HWE) $p < 1 \times 10^{-20}$ and plate effect $p < 1 \times 10^{-6}$. HWE was calculated among control samples for each cohort. Plate effect represents an association test of nondifferential missingness with the plate on which each sample was genotyped.

297 Imputation

Following sample (Supplementary Table 8) and SNP (Supplementary Table 9) QC, genotypes at 351,236 autosomal SNPs from 612 samples (Malawi) and genotypes at 367,433 autosomal SNPs from 350 samples (Mali) were taken forward for phasing and genome-wide imputation. We performed phasing of genotypes in SHAPEIT2 (Delaneau et al., 2012), phasing genotypes across each chromosome for all samples from each country jointly. We then imputed untyped autosomal genotypes using IMPUTE2 (v2.3.0) (B. Howie et al., 2011; B. N. Howie et al., 2009), in 5Mb chunks using the 1000 Genomes Phase III as a reference panel. We used 250kb buffer regions and effective sample size of 20,000.

305 HLA imputation

³⁰⁶ We used HLA*IMP:03 (Motyer et al., 2016) to impute classical HLA alleles into our datasets. As input ³⁰⁷ to HLA*IMP we used genotypes passing sample and SNP QC thresholds in the HLA region (chr6:28Mb-³⁰⁸ 36Mb). HLA*IMP:03 uses a multi-population reference panel, including individuals of African ancestry. ³⁰⁹ HLA imputation performed well, with estimated imputation accuracies ranging between 95% and 99.8%. ³¹⁰ We took forward HLA alleles present in both Malawi and Malawi (MAF > 1%), including 93 classical ³¹¹ alleles (42 class I and 51 class II) in downstream analysis.

312 Additional cross-platform quality control

We noted that relatively few Mali control samples (n=142) were available for inclusion in the association 313 analysis. To address this, we used genotypes from additional control samples (n=183) of representative 314 ethnicity collected as part of the MalariaGEN project (Malaria Genomic Epidemiology, 2019; Toure et 315 al., 2012). These samples have been genotyped on the Illumina Omni 2.5M platform. Sample genotypes 316 have been phased using SHAPEIT2 (Delaneau et al., 2012) and untyped genotypes imputed genome-wide 317 using IMPUTE2 (v2.3.2) (B. Howie et al., 2011; B. N. Howie et al., 2009) with 1000 Genomes Phase 318 III as a reference panel. The SNP and sample QC used in processing these samples (Malaria Genomic 319 Epidemiology, 2019) is highly analogous to the QC we applied to our study samples. MalariaGEN SNP 320 QC excluded poorly genotyped SNPs using the following metrics; SNP missingness (thresholds 2.5-10% 321 dependent on study population), MAF < 1%, HWE $p < 1 \times 10^{-20}$, plate effect $p < 1 \times 10^{-3}$ and a 322 recall test quantifying changes in genotype following a re-clustering process $p < 1 \times 10^{-6}$. MalariaGEN 323 sample QC excluded samples prior to imputation according to the following metrics; channel intensity, 324 missingness, heterozygosity (outlier thresholds determined by ABERRANT (Bellenguez et al., 2012)), 325 population outliers and duplicated samples (relatedness > 0.75). Of note, related samples (relatedness 326 > 0.2) are retained for imputation purposes. 327

We defined a shared subset of SNPs genotyped and passing SNP QC on both platforms (n = 26, 136), from which we calculated relatedness estimates and PCs. We removed one of related pairs (relatedness > 0.2) from the MalariaGEN samples, which resulted in a final sample size of 519 (208 cases, 311 controls). Inspection of the PCs demonstrate no further population outliers, and that the 10 major PCs are nondifferential with respect to genotyping array (Supplementary Fig. 10).

333 Association analysis

Following imputation, SNPs were taken forward for association analysis if they passed the following QC metrics; MAF > 4%, imputation info score > 0.4, HWE $p < 1 \times 10^{-10}$. For the Mali samples, these QC filters were applied overall and for samples genotyped on each genotyping platform individually. At each

variant passing QC we tested for association with leprosy case-control status in a logistic regression model 337 in SNPTEST (Marchini et al., 2007) in each cohort. At loci of interest, we used multinomial logistic 338 regression, implemented in SNPTEST, to estimate the effect of the genetic variation on leprosy risk 339 stratified by multibacillary and paucibacillary disease. We used control status as the baseline stratum 340 and cases of multibacillary and paucibacillary leprosy as strata. To account for confounding variation, in 341 particular population structure, we included the six major principal components of genotyping data in 342 all models. In addition, in Mali, we included genotyping platform as an additional categorical covariate. 343 At variants passing QC thresholds in both cohorts, we then performed genome-wide meta-analysis under 344 a frequentist fixed-effects model using BINGWA (Band et al., 2015). For association analysis using HLA 345 allele imputations we coded posterior probabilities of each HLA allele to represent carriage of 0, 1 or 2 346 copies of that allele. Association analysis and meta-analysis was performed in SNPTEST and BINGWA 347 as above. For HLA association analysis we corrected for the number of classical alleles tested (n=93)348 and considered FDR < 0.05 to be significant. 349

³⁵⁰ Bayesian comparison of models of association

We compared models of association at loci of interest with multibacillary and paucibacillary leprosy, as estimated by multinomial logistic regression, using a Bayesian approach. We considered four models of effect, defined by the prior distributions on the effect size:

"Null": effect size = 0, i.e. no association with leprosy.

"MB": effect size $N(0, 0.2^2)$ for multibacillary disease, but no effect in paucibacillary disease.

"PB": effect size $N(0, 0.2^2)$ for paucibacillary disease, but no effect in multibacillary disease.

"Both": effect size $N(0, 0.2^2)$ and fixed between multibacillary and paucibacillary disease ($\rho = 1$).

For each model we calculated approximate Bayes factors (Wakefield, 2009) and posterior probabilities, assuming each model to be equally likely a priori. Statistical analysis was performed in R.

³⁶⁰ Definition of credible SNP sets

We used a Bayesian approach to identify a set of SNPs with 95% probability of containing the causal locus at the leprosy susceptibility locus at chr10q24.32. Approximate Bayes' factors (Wakefield, 2009) were calculated for each SNP in the region (a 200kb surrounding rs2015583) with a prior distribution of $N(0, 0.2^2)$. All SNPs were considered equally likely to be the causal variant a priori. A set of SNPs with 95% probability of containing the causal SNP was defined as the smallest number of SNPs for which the summed posterior probabilities exceed 0.95.

eQTL mapping and colocalization analysis 367

We used the R package coloc (Giambartolomei et al., 2014) to identify evidence of causal variants 368 shared by eQTL in primary immune cells and GWAS-identified trait associated loci (including leprosy). 369 Coloc adopts a Bayesian approach to compare evidence for independent or shared association signals 370 for two traits at a given genetic locus. We tested for colocalization between leprosy susceptibility at 371 the chr10q24.32 locus and previously-published eQTL mapping studies in naïve and stimulated primary 372 immune cells from individuals of European ancestry (Fairfax et al., 2014; Fairfax et al., 2012; Gilchrist 373 et al., 2021; Kasela et al., 2017; Naranbhai et al., 2015); NK cells (n = 245), B cells (n = 283), monocytes 374 (n = 414), CD4⁺ T cells (n = 293), CD8⁺ T cells (n = 283), neutrophils (n = 101), LPS-stimulated 375 monocytes (2 hours, n = 261; 24 hours, n = 322) and IFN γ -stimulated monocytes (n = 267). We 376 considered evidence for colocalization for each gene within a 250kb window of the peak leprosy associ-377 ation (rs2015583). We considered a posterior probability > 0.8 supporting a shared causal locus to be 378 significant. 379

To assess evidence for pleiotropy with other disease traits we again used coloc to test for the presence of 380 a shared causal locus between the ACTR1A eQTL in CD4⁺ T cells and 55 GWAS traits (Supplementary 381 Table 4); hematological indices (n = 26) and immune-mediated diseases (n = 13) from the UK Biobank 382 (http://www.nealelab.is/uk-biobank/, accessed 26th March 2021), immune-mediated diseases from the 383 NHGRI-EBI GWAS Catalog (n = 13, ftp://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/, ac-384 cessed 26th March 2021), and inflammatory bowel disease traits from the International Inflammatory 385 Bowel Disease Genetics Consortium (n = 3, https://www.ibdgenetics.org/downloads.html, accessed 26th 386 March 2021). 387

Data Availability 388

On publication, genotype and phenotype data for Malawian and Malian cases and controls will be made 389 available via the European Genotype-Phenome Archive. Genotype and phenotype data describing the 390 MalariaGEN Malian samples have been deposited in the European Genome-Phenome Archive (EGA; 391 study accession EGAS00001001311). Access to MalariaGEN datasets on EGA is by application to an 392 independent data access committee. On publication, a full set of association summary statistics will 393 be made available for download through the the NHGRI-EBI GWAS Catalog (https://www.ebi.ac.uk/ 394 gwas/downloads/summary-statistics). 395

396 Acknowledgements

This publication uses genotyping data from the MalariaGEN consortial project, as described in Malaria 397 Genomic Epidemiology Network, et al. Nature Communications, 2019 (https://doi.org/10.1038/s41467-398 019-13480-z). We thank Stuart Mucklow and Giles Warner for their assistance in collecting samples in 399 Mali. JJG and AJM are funded by National Institute for Health Research (NIHR) Clinical Lectureships. 400 During this work AVSH was supported by a Wellcome Trust Senior Investigator Award (HCUZZO) and 401 by a European Research Council advanced grant (294557). The research was supported by the Wellcome 402 Trust Core Award Grant Number 203141/Z/16/Z with additional support from the NIHR Oxford BRC. 403 The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the 404 Department of Health and Social Care. 405

$_{406}$ References

- Ahn, S. J., Costa, J., & Emanuel, J. R. (1996). Picogreen quantitation of dna: Effective evaluation of
 samples pre- or post-pcr. Nucleic Acids Res, 24(13), 2623-2625. https://doi.org/10.1093/nar/
 24.13.2623
- Band, G., Rockett, K. A., Spencer, C. C. A., & Kwiatkowski, D. P. (2015). A novel locus of resistance to severe malaria in a region of ancient balancing selection. *Nature*, 526(7572), 253–257. https://doi.org/10.1000/10000/1000/1000/10000/1000/1000/10000/1000/1000/1000/1000/1000/100
- 412 //doi.org/10.1038/nature15390
- Bellenguez, C., Strange, A., Freeman, C., Donnelly, P., & Spencer, C. C. A. (2012). A robust clustering algorithm for identifying problematic samples in genome-wide association studies. *Bioinformatics*,
 28(1), 134–135. https://doi.org/10.1093/bioinformatics/btr599
- 416 Bossini-Castillo, L., Glinos, D. A., Kunowska, N., Golda, G., Lamikanra, A., Spitzer, M., Soskic, B., Cano-
- 417 Gamez, E., Smyth, D. J., Cattermole, C., Alasoo, K., Mann, A., Kundu, K., Soranzo, N., Dun-
- ham, I., Roberts, D., & Trynka, G. (2019). Immune disease variants modulate gene expression in
- regulatory cd4+ t cells and inform drug targets. *bioRxiv*, https://www.biorxiv.org/content/early/2019/05/31/654
 https://doi.org/10.1101/654632
- Britton, W. J. (1998). The management of leprosy reversal reactions. Lepr Rev, 69(3), 225–234. https:
 //doi.org/10.5935/0305-7518.19980024
- Britton, W. J., & Lockwood, D. N. J. (2004). Leprosy. Lancet, 363(9416), 1209–1219. https://doi.org/
 10.1016/S0140-6736(04)15952-7
- ⁴²⁵ Chemotherapy of leprosy. report of a who study group. (1994). World Health Organ Tech Rep Ser, 847,
 ⁴²⁶ 1–24.
- ⁴²⁷ Delaneau, O., Marchini, J., & Zagury, J.-F. (2012). A linear complexity phasing method for thousands
 ⁴²⁸ of genomes. *Nature Methods*, 9(2), 179–181. https://doi.org/10.1038/nmeth.1785

429	Fairfax, B. P., Humburg, P., Makino, S., Naranbhai, V., Wong, D., Lau, E., Jostins, L., Plant, K.,
430	Andrews, R., McGee, C., & Knight, J. C. (2014). Innate immune activity conditions the effect
431	of regulatory variants upon monocyte gene expression. Science, $343(6175)$, 1246949. https://
432	doi.org/10.1126/science.1246949
433	Fairfax, B. P., Makino, S., Radhakrishnan, J., Plant, K., Leslie, S., Dilthey, A., Ellis, P., Langford, C.,
434	Vannberg, F. O., & Knight, J. C. (2012). Genetics of gene expression in primary immune cells
435	identifies cell type-specific master regulators and roles of hla alleles. Nat Genet, $44(5)$, 502–510.
436	https://doi.org/10.1038/ng.2205
437	Fitness, J., Floyd, S., Warndorff, D. K., Sichali, L., Mwaungulu, L., Crampin, A. C., Fine, P. E. M., &
438	Hill, A. V. S. (2004). Large-scale candidate gene study of leprosy susceptibility in the karonga
439	district of northern malawi. Am J Trop Med Hyg, 71(3), 330–340.
440	for South-East Asia, W. H. O. R. O. (2009). Enhanced global strategy for further reducing the disease
441	burden due to leprosy (2011-2015): Plan period: 2011-2015). WHO Regional Office for South-
442	East Asia.
443	Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol,
444	V. (2014). Bayesian test for colocalisation between pairs of genetic association studies using
445	summary statistics. PLoS Genet, $10(5)$, e1004383. https://doi.org/10.1371/journal.pgen.1004383
446	Gilchrist, J. J., Makino, S., Naranbhai, V., Lau, E., Danielli, S., Hameiri-Bowen, D., Lee, W., Ng,
447	E., Whalley, J., Knight, J. C., & Fairfax, B. P. (2021). Natural killer cells demonstrate dis-
448	tinct eqtl and transcriptome-wide disease associations, highlighting their role in autoimmunity.
449	$bioRxiv,\ https://www.biorxiv.org/content/early/2021/05/11/2021.05.10.443088.full.pdf.\ https://www.biorxiv.org/content/early/2021/05/11/2021.05.10.443088.full.pdf.\ https://www.biorxiv.org/content/early/2021/05/11/2021.05.10.443088.full.pdf.$
450	//doi.org/10.1101/2021.05.10.443088
451	Gurdasani, D., Carstensen, T., Tekola-Ayele, F., Pagani, L., Tachmazidou, I., Hatzikotoulas, K., Karthikeyan, S., Karthikey
452	S., Iles, L., Pollard, M. O., Choudhury, A., Ritchie, G. R. S., Xue, Y., Asimit, J., Nsubuga, R. N.,
453	Young, E. H., Pomilla, C., Kivinen, K., Rockett, K., Kamali, A., Sandhu, M. S. (2015). The
454	a frican genome variation project shapes medical genetics in a frica. Nature, $517(7534)$, $327-332$.
455	https://doi.org/10.1038/nature13997
456	Gzara, C., Dallmann-Sauer, M., Orlova, M., Van Thuc, N., Thai, V. H., Fava, V. M., Bihoreau, MT.,
457	Boland, A., Abel, L., Alcais, A., Schurr, E., & Cobat, A. (2020). Family-based genome-wide
458	association study of leprosy in vietnam. PLoS Pathog, $16(5)$, $e1008565$. $https://doi.org/10$.
459	1371/journal.ppat.1008565
460	Hashimoto-Tane, A., Yokosuka, T., Sakata-Sogawa, K., Sakuma, M., Ishihara, C., Tokunaga, M., & Saito,
461	T. (2011). Dynein-driven transport of t cell receptor microclusters regulates immune synapse
462	formation and t cell activation. Immunity, $34(6)$, $919-931$. https://doi.org/10.1016/j.immuni.
463	2011.05.012

18

- Howie, B., Marchini, J., & Stephens, M. (2011). Genotype imputation with thousands of genomes. G3 464 (Bethesda), 1(6), 457–470. https://doi.org/10.1534/g3.111.001198 465 Howie, B. N., Donnelly, P., & Marchini, J. (2009). A flexible and accurate genotype imputation method 466 for the next generation of genome-wide association studies. *PLoS Genet*, 5(6), e1000529. https: 467 //doi.org/10.1371/journal.pgen.1000529 468 Johnston, H. R., Hu, Y.-J., Gao, J., O'Connor, T. D., Abecasis, G. R., Wojcik, G. L., Gignoux, C. R., 469 Gourraud, P.-A., Lizee, A., Hansen, M., Genuario, R., Bullis, D., Lawley, C., Kenny, E. E., 470 Bustamante, C., Beaty, T. H., Mathias, R. A., Barnes, K. C., & Qin, Z. S. (2017). Identifying 471 tagging snps for african specific genetic variation from the african diaspora genome. Sci Rep. 7, 472 46398. https://doi.org/10.1038/srep46398 473 Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Schumm, 474 L. P., Sharma, Y., Anderson, C. A., Essers, J., Mitrovic, M., Ning, K., Cleynen, I., Theatre, E., 475 Spain, S. L., Raychaudhuri, S., Goyette, P., Wei, Z., ... Cho, J. H. (2012). Host-microbe inter-476 actions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 477 119-124. https://doi.org/10.1038/nature11582 478 Kasela, S., Kisand, K., Tserel, L., Kaleviste, E., Remm, A., Fischer, K., Esko, T., Westra, H.-J., Fairfax, 479 B. P., Makino, S., Knight, J. C., Franke, L., Metspalu, A., Peterson, P., & Milani, L. (2017). 480 Pathogenic implications for autoimmune mechanisms derived by comparative eqtl analysis of 481 cd4+ versus cd8+ t cells. *PLoS Genet*, 13(3), e1006643. https://doi.org/10.1371/journal.pgen. 482 1006643 483 Liu, H., Irwanto, A., Fu, X., Yu, G., Yu, Y., Sun, Y., Wang, C., Wang, Z., Okada, Y., Low, H., Li, Y., 484 Liany, H., Chen, M., Bao, F., Li, J., You, J., Zhang, Q., Liu, J., Chu, T., ... Zhang, F. (2015). 485 Discovery of six new susceptibility loci and analysis of pleiotropic effects in leprosy. Nat Genet, 486 47(3), 267–271. https://doi.org/10.1038/ng.3212 487 Liu, H., Wang, Z., Li, Y., Yu, G., Fu, X., Wang, C., Liu, W., Yu, Y., Bao, F., Irwanto, A., Liu, J., Chu, 488 T., Andiappan, A. K., Maurer-Stroh, S., Limviphuvadh, V., Wang, H., Mi, Z., Sun, Y., Sun, 489 L., ... Zhang, F. (2017). Genome-wide analysis of protein-coding variants in leprosy. J Invest 490 Dermatol, 137(12), 2544-2551. https://doi.org/10.1016/j.jid.2017.08.004 491 Malaria Genomic Epidemiology, N. (2019). Insights into malaria susceptibility using genome-wide data 492 on 17,000 individuals from africa, asia and oceania. Nat Commun, 10(1), 5732. https://doi.org/ 493 10.1038/s41467-019-13480-z 494 Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007). A new multipoint method for 495 genome-wide association studies by imputation of genotypes. Nat Genet, 39(7), 906–913. https: 496
- 497 //doi.org/10.1038/ng2088

Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sand-498 strom, R., Qu, H., Brody, J., Shafer, A., Neri, F., Lee, K., Kutyavin, T., Stehling-Sun, S., John-499 son, A. K., Canfield, T. K., Giste, E., Diegel, M., ... Stamatoyannopoulos, J. A. (2012). System-500 atic localization of common disease-associated variation in regulatory dna. Science, 337(6099), 501 1190-1195. https://doi.org/10.1126/science.1222794 502 Meisner, S. J., Mucklow, S., Warner, G., Sow, S. O., Lienhardt, C., & Hill, A. V. (2001). Association of 503 nramp1 polymorphism with leprosy type but not susceptibility to leprosy per se in west africans. 504 Am J Trop Med Hyg, 65(6), 733-735. https://doi.org/10.4269/ajtmh.2001.65.733 505 Monot, M., Honoré, N., Garnier, T., Zidane, N., Sherafi, D., Paniz-Mondolfi, A., Matsuoka, M., Taylor, 506 G. M., Donoghue, H. D., Bouwman, A., Mays, S., Watson, C., Lockwood, D., Khamesipour, A., 507 Dowlati, Y., Jianping, S., Rea, T. H., Vera-Cabrera, L., Stefani, M. M., ... Cole, S. T. (2009). 508 Comparative genomic and phylogeographic analysis of mycobacterium leprae. Nat Genet, 41(12), 509 1282-1289. https://doi.org/10.1038/ng.477 510 Motyer, A., Vukcevic, D., Dilthey, A., Donnelly, P., McVean, G., & Leslie, S. (2016). Practical use of meth-511 ods for imputation of hla alleles from snp genotype data. bioRxiv, https://www.biorxiv.org/content/early/2016/12 512 https://doi.org/10.1101/091009 513 Naranbhai, V., Fairfax, B. P., Makino, S., Humburg, P., Wong, D., Ng, E., Hill, A. V. S., & Knight, J. C. 514 (2015). Genomic modulators of gene expression in human neutrophils. Nat Commun, 6, 7545. 515 https://doi.org/10.1038/ncomms8545 516 Nath, S., Christian, L., Tan, S. Y., Ki, S., Ehrlich, L. I. R., & Poenie, M. (2016). Dynein separately 517 partners with nde1 and dynactin to orchestrate t cell focused secretion. J Immunol, 197(6), 518 2090-2101. https://doi.org/10.4049/jimmunol.1600180 519 Ponnighaus, J. M., Fine, P. E., & Bliss, L. (1987). Certainty levels in the diagnosis of leprosy. Int J Lepr 520 Other Mycobact Dis, 55(3), 454–462. 521 Pönnighaus, J. M., Fine, P. E., Sterne, J. A., Wilson, R. J., Msosa, E., Gruer, P. J., Jenkins, P. A., Lucas, 522 S. B., Liomba, N. G., & Bliss, L. (1992). Efficacy of bcg vaccine against leprosy and tuberculosis 523 in northern malawi. Lancet, 339(8794), 636–639. https://doi.org/10.1016/0140-6736(92)90794-4 524 Ponninghaus, J. M., Fine, P. E., Bliss, L., Sliney, I. J., Bradley, D. J., & Rees, R. J. (1987). The lepra 525 evaluation project (lep), an epidemiological study of leprosy in northern malaŵi. i. methods. 526 Lepr Rev, 58(4), 359-375. https://doi.org/10.5935/0305-7518.19870038 527 Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006). 528 Principal components analysis corrects for stratification in genome-wide association studies. Nat 529 Genet, 38(8), 904-909. https://doi.org/10.1038/ng1847 530 Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, 531 P., de Bakker, P. I. W., Daly, M. J., & Sham, P. C. (2007). Plink: A tool set for whole-genome

532

533	association and population-based linkage analyses. Am J Hum Genet, $81(3)$, 559–575. https:
534	//doi.org/10.1086/519795
535	Roberts, A. J., Kon, T., Knight, P. J., Sutoh, K., & Burgess, S. A. (2013). Functions and mechanics
536	of dynein motor proteins. Nat Rev Mol Cell Biol, 14(11), 713–726. https://doi.org/10.1038/
537	nrm3667
538	Shrum, C. K., Defrancisco, D., & Meffert, M. K. (2009). Stimulated nuclear translocation of nf-kappab
539	and shuttling differentially depend on dynein and the dynactin complex. Proc Natl Acad Sci U
540	$S~A,~106(8),~2647-2652.~{\rm https://doi.org/10.1073/pnas.0806677106}$
541	Smith, W. C., van Brakel, W., Gillis, T., Saunderson, P., & Richardus, J. H. (2015). The missing millions:
542	A threat to the elimination of leprosy. PLoS Negl Trop Dis, $9(4)$, e0003658. https://doi.org/10.
543	1371/journal.pntd.0003658
544	Sun, Y., Irwanto, A., Toyo-Oka, L., Hong, M., Liu, H., Andiappan, A. K., Choi, H., Hitomi, Y., Yu, G.,
545	Yu, Y., Bao, F., Wang, C., Fu, X., Yue, Z., Wang, H., Zhang, H., Kawashima, M., Kojima, K.,
546	Nagasaki, M., Liu, J. (2016). Fine-mapping analysis revealed complex pleiotropic effect and
547	tissue-specific regulatory mechanism of tnfsf15 in primary biliary cholangitis, crohn's disease and
548	leprosy. Sci Rep, 6, 31429. https://doi.org/10.1038/srep31429
549	Toure, O., Konate, S., Sissoko, S., Niangaly, A., Barry, A., Sall, A. H., Diarra, E., Poudiougou, B.,
550	Sepulveda, N., Campino, S., Rockett, K. A., Clark, T. G., Thera, M. A., & Doumbo, O. (2012).
551	Candidate polymorphisms and severe malaria in a malian population. PLoS One, $7(9)$, e43987.
552	https://doi.org/10.1371/journal.pone.0043987
553	Urnavicius, L., Zhang, K., Diamant, A. G., Motz, C., Schlager, M. A., Yu, M., Patel, N. A., Robinson,
554	C. V., & Carter, A. P. (2015). The structure of the dynactin complex and its interaction with
555	dynein. Science, $347(6229)$, 1441–1446. https://doi.org/10.1126/science.aaa4080
556	Wakefield, J. (2009) . Bayes factors for genome-wide association studies: Comparison with p-values. Genet
557	<i>Epidemiol</i> , 33(1), 79–86. https://doi.org/10.1002/gepi.20359
558	Wallace, C., Fitness, J., Hennig, B., Sichali, L., Mwaungulu, L., Pönnighaus, J. M., Warndorff, D. K.,
559	Clayton, D., Fine, P. E. M., & Hill, A. V. S. (2004). Linkage analysis of susceptibility to leprosy
560	type using an ibd regression method. Genes Immun, $5(3)$, 221–225. https://doi.org/10.1038/sj.
561	gene.6364062
562	Wang, Z., Mi, Z., Wang, H., Sun, L., Yu, G., Fu, X., Wang, C., Bao, F., Yue, Z., Zhao, Q., Wang, N.,
563	Cheng, X., Liu, H., & Zhang, F. (2018). Discovery of 4 exonic and 1 intergenic novel susceptibility
564	loci for leprosy. Clin Genet, $94(2)$, 259–263. https://doi.org/10.1111/cge.13376
565	Wang, Z., Sun, Y., Fu, X., Yu, G., Wang, C., Bao, F., Yue, Z., Li, J., Sun, L., Irwanto, A., Yu, Y.,
566	Chen, M., Mi, Z., Wang, H., Huai, P., Li, Y., Du, T., Yu, W., Xia, Y., Zhang, F. (2016).

567	A large-scale genome-wide association and meta-analysis identified four novel susceptibility loci
568	for leprosy. Nat Commun, 7, 13760. https://doi.org/10.1038/ncomms13760
569	WHO Working Group on Leprosy Control. Meeting (1st: 1991 : Geneva, S., & Unit, W. H. O. L. (1991).
570	Report of the first meeting of the who working group on leprosy control, geneva, 1-3 july 1991.
571	World Health Organization.
572	Wong, S. H., Gochhait, S., Malhotra, D., Pettersson, F. H., Teo, Y. Y., Khor, C. C., Rautanen, A.,
573	Chapman, S. J., Mills, T. C., Srivastava, A., Rudko, A., Freidin, M. B., Puzyrev, V. P., Ali, S.,
574	Aggarwal, S., Chopra, R., Reddy, B. S. N., Garg, V. K., Roy, S., Vannberg, F. O. (2010).
575	Leprosy and the adaptation of human toll-like receptor 1. PLoS Pathog, $6(7)$, e1000979. https:
576	//doi.org/10.1371/journal.ppat.1000979
577	Yamamura, M., Wang, X. H., Ohmen, J. D., Uyemura, K., Rea, T. H., Bloom, B. R., & Modlin, R. L.
578	(1992). Cytokine patterns of immunologically mediated tissue damage. J Immunol, 149(4), 1470–
579	1475.
580	Zhang, FR., Huang, W., Chen, SM., Sun, LD., Liu, H., Li, Y., Cui, Y., Yan, XX., Yang, HT.,
581	Yang, RD., Chu, TS., Zhang, C., Zhang, L., Han, JW., Yu, GQ., Quan, C., Yu, YX.,
582	Zhang, Z., Shi, BQ., Liu, JJ. (2009). Genomewide association study of leprosy. N Engl J
583	$Med,\ 361 (27),\ 2609-2618.\ https://doi.org/10.1056/NEJMoa0903753$
584	Zhang, F., Liu, H., Chen, S., Low, H., Sun, L., Cui, Y., Chu, T., Li, Y., Fu, X., Yu, Y., Yu, G., Shi, B.,
585	Tian, H., Liu, D., Yu, X., Li, J., Lu, N., Bao, F., Yuan, C., Zhang, X. (2011). Identification
586	of two new loci at il23r and rab32 that influence susceptibility to leprosy. Nat Genet, $43(12)$,
587	1247–1251. https://doi.org/10.1038/ng.973

Supplementary Figures 588




Figure S1: Quantile-quantile plots of leprosy association. QQ-plots of leproxy association in Malawi (284 cases, 328 controls, SNPs = 10.511,695), Mali (208 cases, 311 controls, SNPs = 10,514,676) and fixed-effects meta-analysis of both populations (cases = 492, controls = 639, SNPs = 9,616,523).




Figure S2: Manhattan plots of leprosy association. Manhattan plots of leprosy association in discovery (Malawi, 284 cases, 328 controls, SNPs = 10,511,695) and replication (Mali, 208 cases, 311 controls, SNPs = 10,514,676) samples. P-value thresholds are annotated on the Malawi Manhattan plot: dashed line, $p = 1 \times 10^{-8}$ (genome-wide significance); dotted line, $p = 1 \times 10^{-5}$ (threshold for suggestive association).






Figure S3: HLA Leprosy association conditioned on HLA-DQB1*04:02. Association statistics represent a fixed-effects meta-analysis of additive association with disease in Malawi and Mali conditioned on HLA-DQB1*04:02. SNPs are coloured according to linkage disequilibrium to rs2516438, and genotyped SNPs marked with black plusses. Imputed classical HLA alleles are plotted as diamonds, with significantly associated (FDR < 0.05) alleles highlighted in blue.






Figure S4: HLA Leprosy association conditioned on HLA-DQB1*04:02 and HLA-B*49:01. Association statistics represent a fixed-effects meta-analysis of additive association with disease in Malawi and Mali conditioned on HLA-DQB1*04:02 and HLA-B*49:01. SNPs are coloured according to linkage disequilibrium to rs115312361, and genotyped SNPs marked with black plusses. Imputed classical HLA alleles are plotted as diamonds. No significantly associated (FDR < 0.05) alleles remain after conditioning on HLA-DQB1*04:02 and HLA-B*49:01.





(A) Log-transformed odds ratios and 95% confidence intervals of rs2275606 association (peak association in Chinese GWAS data) with leprosy in Malawi, Mali and China. (B) Log-transformed odds ratios and 95% confidence intervals of rs34271799 association with leprosy in Malawi and Mali. (C) Regional association plot of leprosy association at the RAB32 locus. Association statistics represent a fixed-effects meta-analysis of additive association with disease in Malawi and Mali. SNPs are coloured according to linkage disequilibrium to rs34271799, and genotyped SNPs marked with black plusses.




Figure S6: **Sample X and Y channel intensities.** (A) Mean X and Y channel intensities for Malawi (top) and Mali (bottom) samples. Outlying samples were identified using ABERRANT and are highlighted (orange).




Figure S7: **Sample missingness and heterozygosity.** (A) Mean sample genotype missingness plotted against heterozygosity for Malawi (top) and Mali (bottom) samples. Outlying samples were identified using ABERRANT and are highlighted (orange).




Figure S8: Population outliers.

Plot of the major two principal components of genome wide genotyping data. Malawi study samples are plotted in orange and Mali study samples in green, against a background of African Genome Variation Project samples (gray). Outliers are highlighted (black rings).






Figure S9: Principal components of Malawian genome-wide genotyping data. Individuals are color-coded according to self-reported ethnicity (top) and case-control status; cases in pink, controls in green (bottom).




Figure S10: Principal components of Malian genome-wide genotyping data. Individuals are color-coded according to self-reported ethnicity (top), case-control status (middle; cases in pink, controls in green), and genotyping platform (bottom; Omni 2.5M in purple, Africa Diaspora Power Chip in gray).